Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 184 participants.
Also called NCT02941367
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 184 participants
- Sponsor
- Registry
-
NCT02941367
-
- Other papers using this trial's data
- Safety of lixisenatide plus basal insulin treatment regimen in Indian people with type 2 diabetes mellitus during Ramadan fast: A post hoc analysis of the LixiRam randomized trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- India, Israel, Kuwait, Türkiye
- Registry status
- Completed
Technical summary
Registry record NCT02941367. Randomized; no masking; primary purpose treatment. Start 2017-02-23 (actual); primary completion 2017-08-04 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety Assessment of Lyxumia (Lixisenatide) and Sulfonylurea as Add-on Treatment to Basal Insulin in Uncontrolled Patients With Type 2 Diabetes Mellitus Who Elect to Fast During Ramadan
- Acronym
- LixiRam
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- Lixisenatide (AVE0010)
- Intervention (Drug)
- Sulfonylurea
- Intervention (Drug)
- metformin
- Intervention (Drug)
- basal insulin
- Lead sponsor
- Sanofi
Record details
- Record id
cardio:ct-nct02941367- Content hash
aaf98583b9bcf4f73af4cc37798f33c0526fb61dc79279178d9177d2bca4a82d